i-SENS

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, i-SENS sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting upper half by trial count

i-SENS: 2 sponsored US clinical trials, 1 recruiting.

i-SENS sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. The most-studied condition in this pipeline is Type 1 Diabetes Mellitus, with 1 trials.

Mid-pack sponsor footprint

i-SENS is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

2 total, page 1 of 1

RECRUITING NA

Accuracy and Precision of the Continuous Glucose Monitoring System 'CareSens Air 3' in Adult Patients With T1DM

NCT07296276
TERMINATED NA

Method Comparison/User Evaluation of the i-SENS Self-Monitoring Blood Glucose / β-Ketone System

NCT05833100

Therapeutic Areas

Type 1 Diabetes Mellitus 1

What is open in the i-SENS pipeline

1 recruiting of 2 indexed (50% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Type 1 Diabetes Mellitus (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

i-SENS: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

i-SENS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share i-SENS1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
i-SENS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

i-SENS sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this i-SENS page

2 registered trials is a research-attention snapshot, not an endorsement of i-SENS or any single study.

  • 1 of i-SENS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Type 1 Diabetes Mellitus is the condition i-SENS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Type 1 Diabetes Mellitus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

i-SENS pipeline card: 2 registered trials from official public datasets.Report a data error.